Selected research
Industry Research
Endoparasiticide Industry Research Report 2026
Market perspective
The global Endoparasiticide market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Endoparasiticide is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Endoparasiticide is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Endoparasiticide is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Endoparasiticide include Novartis AG, Merck, Eli Lilly, Bayer AG, Zoetis, Virbac, Vetoquinol, Elanco and Ceva Sante Animlae, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Endoparasiticide market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Endoparasiticide Market by Company
Novartis AG
Merck
Eli Lilly
Bayer AG
Zoetis
Virbac
Vetoquinol
Elanco
Ceva Sante Animlae
Boehringer Ingelheim
Endoparasiticide Segment by Type
Ear Tags
Feed Additives
Tablets
Injectables
Endoparasiticide Segment by Application
Veterinary Hospitals or Clinics
Home Care Settings
Animal Farms
Endoparasiticide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endoparasiticide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Endoparasiticide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endoparasiticide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Endoparasiticide manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Endoparasiticide by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Endoparasiticide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ear Tags
- Feed Additives
- Tablets
- Injectables
Applications
- Veterinary Hospitals or Clinics
- Home Care Settings
- Animal Farms
Companies covered
- Novartis AG
- Merck
- Eli Lilly
- Bayer AG
- Zoetis
- Virbac
- Vetoquinol
- Elanco
- Ceva Sante Animlae
- Boehringer Ingelheim
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Endoparasiticide Market Size (2021-2032)
- 2.2.2 Global Endoparasiticide Sales (2021-2032)
- 2.2.3 Global Endoparasiticide Market Average Price (2021-2032)
- 2.3 Endoparasiticide by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ear Tags
- 2.3.3 Feed Additives
- 2.3.4 Tablets
- 2.3.5 Injectables
- 2.4 Endoparasiticide by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Veterinary Hospitals or Clinics
- 2.4.3 Home Care Settings
- 2.4.4 Animal Farms
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Endoparasiticide Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Endoparasiticide Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Endoparasiticide Revenue of Manufacturers (2021-2026)
- 3.4 Global Endoparasiticide Average Price by Manufacturers (2021-2026)
- 3.5 Global Endoparasiticide Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Endoparasiticide, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Endoparasiticide, Product Type & Application
- 3.8 Global Manufacturers of Endoparasiticide, Established Date
- 3.9 Global Endoparasiticide Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Endoparasiticide Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Endoparasiticide Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck Endoparasiticide Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck Endoparasiticide Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 Eli Lilly
- 4.3.1 Eli Lilly Company Information
- 4.3.2 Eli Lilly Business Overview
- 4.3.3 Eli Lilly Endoparasiticide Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Eli Lilly Endoparasiticide Product Portfolio
- 4.3.5 Eli Lilly Recent Developments
- 4.4 Bayer AG
- 4.4.1 Bayer AG Company Information
- 4.4.2 Bayer AG Business Overview
- 4.4.3 Bayer AG Endoparasiticide Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Bayer AG Endoparasiticide Product Portfolio
- 4.4.5 Bayer AG Recent Developments
- 4.5 Zoetis
- 4.5.1 Zoetis Company Information
- 4.5.2 Zoetis Business Overview
- 4.5.3 Zoetis Endoparasiticide Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Zoetis Endoparasiticide Product Portfolio
- 4.5.5 Zoetis Recent Developments
- 4.6 Virbac
- 4.6.1 Virbac Company Information
- 4.6.2 Virbac Business Overview
- 4.6.3 Virbac Endoparasiticide Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Virbac Endoparasiticide Product Portfolio
- 4.6.5 Virbac Recent Developments
- 4.7 Vetoquinol
- 4.7.1 Vetoquinol Company Information
- 4.7.2 Vetoquinol Business Overview
- 4.7.3 Vetoquinol Endoparasiticide Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Vetoquinol Endoparasiticide Product Portfolio
- 4.7.5 Vetoquinol Recent Developments
- 4.8 Elanco
- 4.8.1 Elanco Company Information
- 4.8.2 Elanco Business Overview
- 4.8.3 Elanco Endoparasiticide Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Elanco Endoparasiticide Product Portfolio
- 4.8.5 Elanco Recent Developments
- 4.9 Ceva Sante Animlae
- 4.9.1 Ceva Sante Animlae Company Information
- 4.9.2 Ceva Sante Animlae Business Overview
- 4.9.3 Ceva Sante Animlae Endoparasiticide Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Ceva Sante Animlae Endoparasiticide Product Portfolio
- 4.9.5 Ceva Sante Animlae Recent Developments
- 4.10 Boehringer Ingelheim
- 4.10.1 Boehringer Ingelheim Company Information
- 4.10.2 Boehringer Ingelheim Business Overview
- 4.10.3 Boehringer Ingelheim Endoparasiticide Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Boehringer Ingelheim Endoparasiticide Product Portfolio
- 4.10.5 Boehringer Ingelheim Recent Developments
5 Global Endoparasiticide Market Scenario by Region
- 5.1 Global Endoparasiticide Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Endoparasiticide Sales by Region: 2021-2032
- 5.2.1 Global Endoparasiticide Sales by Region: 2021-2026
- 5.2.2 Global Endoparasiticide Sales by Region: 2027-2032
- 5.3 Global Endoparasiticide Revenue by Region: 2021-2032
- 5.3.1 Global Endoparasiticide Revenue by Region: 2021-2026
- 5.3.2 Global Endoparasiticide Revenue by Region: 2027-2032
- 5.4 North America Endoparasiticide Market Facts & Figures by Country
- 5.4.1 North America Endoparasiticide Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Endoparasiticide Sales by Country (2021-2032)
- 5.4.3 North America Endoparasiticide Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Endoparasiticide Market Facts & Figures by Country
- 5.5.1 Europe Endoparasiticide Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Endoparasiticide Sales by Country (2021-2032)
- 5.5.3 Europe Endoparasiticide Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Endoparasiticide Market Facts & Figures by Country
- 5.6.1 Asia Pacific Endoparasiticide Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Endoparasiticide Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Endoparasiticide Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Endoparasiticide Market Facts & Figures by Country
- 5.7.1 South America Endoparasiticide Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Endoparasiticide Sales by Country (2021-2032)
- 5.7.3 South America Endoparasiticide Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Endoparasiticide Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Endoparasiticide Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Endoparasiticide Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Endoparasiticide Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Endoparasiticide Sales by Type (2021-2032)
- 6.1.1 Global Endoparasiticide Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Endoparasiticide Sales Market Share by Type (2021-2032)
- 6.2 Global Endoparasiticide Revenue by Type (2021-2032)
- 6.2.1 Global Endoparasiticide Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Endoparasiticide Revenue Market Share by Type (2021-2032)
- 6.3 Global Endoparasiticide Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Endoparasiticide Sales by Application (2021-2032)
- 7.1.1 Global Endoparasiticide Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Endoparasiticide Sales Market Share by Application (2021-2032)
- 7.2 Global Endoparasiticide Revenue by Application (2021-2032)
- 7.2.1 Global Endoparasiticide Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Endoparasiticide Revenue Market Share by Application (2021-2032)
- 7.3 Global Endoparasiticide Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Endoparasiticide Value Chain Analysis
- 8.1.1 Endoparasiticide Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Endoparasiticide Production Mode & Process
- 8.2 Endoparasiticide Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Endoparasiticide Distributors
- 8.2.3 Endoparasiticide Customers
9 Global Endoparasiticide Analyzing Market Dynamics
- 9.1 Endoparasiticide Industry Trends
- 9.2 Endoparasiticide Industry Drivers
- 9.3 Endoparasiticide Industry Opportunities and Challenges
- 9.4 Endoparasiticide Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst